CTOs on the Move

Otsego Memorial Hospital

www.myomh.org

 
Otsego Memorial Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Gaylord, MI. To find more information about Otsego Memorial Hospital, please visit www.myomh.org
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.myomh.org
  • 825 N Center Ave
    Gaylord, MI USA 49735-1592
  • Phone: 989.731.2100

Executives

Name Title Contact Details

Similar Companies

Iris Plans

Iris Plans provides telehealth Advance Care Planning (ACP) services to health insurers and health care providers, reducing unnecessary care for people with serious medical conditions. ACP lowers the cost of care while improving quality and experience.

Aviacode

Aviacode is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Salt Lake City, UT. To find more information about Aviacode, please visit www.aviacode.com

Ra Pharmaceuticals

Ra Pharma combines novel insights into complement and other innate immunity pathways with leadership in macrocycle technology to transform the lives of patients with life threatening disorders.

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.

NeoMend

NeoMend is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.